[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336567-105":59,"doc-detail-336567-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liraglutide-enhances-the-effect-of-checkpoint-blockade-in-lung-and-liver-cancers-through-the-inhibition-of-neutrophil-extracellular-traps","Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps","","Liraglutide, a long-acting GLP-1 analog, is investigated for its role in the development and therapy of murine lung and liver cancers. The study shows liraglutide markedly reduces circulating NET markers (myeloperoxidase, elastase, and dsDNA) in Lewis lung cancer and Hepa1-6 tumor-bearing mice, and downregulates NETs and neutrophil ROS in the tumor microenvironment. Liraglutide also inhibits NET formation in vitro via ROS, and strengthens PD-1 inhibition efficacy; however, NET removal weakens this antitumor benefit. Combined therapy drives durable CD8+ T-cell responses that reject tumor rechallenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liraglutide-enhances-the-effect-of-checkpoint-blockade-in-lung-and-liver-cancers-through-the-inhibition-of-neutrophil-extracellular-traps/336567/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liraglutide-enhances-the-effect-of-checkpoint-blockade-in-lung-and-liver-cancers-through-the-inhibition-of-neutrophil-extracellular-traps/336567.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does liraglutide affect neutrophil extracellular traps (NETs) in cancer models?","Question",{"text":112,"@type":113},"Liraglutide substantially decreases circulating NET markers and reduces NETs in the tumor microenvironment. In vitro, it reduces NET formation by inhibiting neutrophil ROS.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the relationship between liraglutide and PD-1 checkpoint blockade?",{"text":117,"@type":113},"Liraglutide enhances the anti-tumoral efficiency of PD-1 inhibition in Lewis lung cancer and Hepa1-6 tumor-bearing mice. This enhancement is dependent on NETs.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens to treatment efficacy when NETs are removed?",{"text":121,"@type":113},"Removal of NETs significantly weakens the antitumor efficiency of liraglutide, indicating that NETs reduction is a key contributor to the therapeutic effect.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336567,1790791503,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \nLiraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps  \nDuo Chen 1 , Hongxin Liang2, Luyu Huang3, Haiyu Zhou2 and Zheng Wang 1  \n1 Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China  \n2 Department of Thoracic Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China  \n3 Department of Surgery, Competence Center of Thoracic Surgery, Charit Universit€atsmedizin Berlin, Germany  \nKeywords  \nliraglutide; liver cancer; lung cancer; neutrophil extracellular traps; PD-1  \nCorrespondence  \nZ. Wang and D. Chen, Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical  \nUniversity, Beijing 100020, China E-mails: [azheng178@163.com](azheng178@163.com) (ZW);  \n[chenduozx2751@163.com](chenduozx2751@163.com) (DC) and  \nH. Zhou, Department of Thoracic Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510100, China  \nE-mail: [zhouhaiyu@gdph.org.cn](zhouhaiyu@gdph.org.cn)  \n(Received 3 May 2022, revised 20  \nSeptember 2022, accepted 20 October 2022)  \ndoi:10.1002/2211-5463.13499  \nGlucagon-like peptide-1 (GLP-1) regulates glycemic excursions by augmenting insulin production and inhibiting glucagon secretion. Liraglutide, a long-acting GLP-1 analog, can improve glycemic control for treating type 2 diabetes and prevent neutrophil extravasation in inﬂammation. Here, we explored the role of liraglutide in the development and therapy of murine lung and liver cancers. In this study, liraglutide substantially decreased circulating neutrophil extracellular trap (NET) markers myeloperoxidase, elastase, and dsDNA in Lewis lung cancer (LLC) and Hepa1-6 tumorbearing mice. Furthermore, liraglutide downregulated NETs and reactive oxygen species (ROS) of neutrophils in the tumor microenvironment. Functionally, in vitro experiments showed that liraglutide reduced NET formation by inhibiting ROS. In addition, we showed that liraglutide enhanced the anti-tumoral efﬁciency of programmed cell death-1 (PD-1) inhibition in LLC and Hepa1-6 tumor-bearing C57BL/6 mice. However, the removal of NETs signiﬁcantly weakened the antitumor efﬁciency of liraglutide. We further demonstrated that the long-term antitumor CD8+ T cell responses induced by the combination therapy rejected rechallenges by respective tumor cell lines. Taken together, our ﬁndings suggest that liraglutide may promote the anti-tumoral efﬁciency of PD-1 inhibition by reducing NETs in lung and liver cancers.  \nGlucagon-like peptide-1 (GLP-1) could regulate glycemic excursions by augmenting insulin production and inhibiting glucagon secretion [1] . Liraglutide, a longacting GLP-1 analog with 97% structural homology to the native hormone [2], binds to the GLP-1 receptor, displaying a similarly broad range of activities relevant to improving glycemic control for treating type 2 diabetes. Additionally, GLP-1 receptor agonists, including  \nliraglutide, are safe and not associated with an  \nincreased risk of pancreatic and breast cancer [3–5] .  \nFurthermore, liraglutide presented anticancer effects on breast cancer cells [3] . However, the inﬂuence of liraglutide on other cancers is yet to be reported. In addition, GLP-1 also has immune modulatory roles. It was reported that GLP-1 stimulation regulated eosinophil activation in allergic asthmatic subjects [6] and  \nAbbreviations  \nGLP-1, glucagon-like peptide-1; ICIs, immune checkpoint inhibitors; LLC, Lewis lung cancer; NETs, neutrophil extracellular traps; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; ROS, reactive oxygen species; STR, surgical tumor resection.  \nFEBS Open Bio 14 (2024) 1365–1377 􀀁 2022 The Authors. FEBS Open Bio published by Jo","cbCaiggeQKl0jBaK","https://ap.wps.com/l/cbCaiggeQKl0jBaK","pdf",2318326,13,"English","# Introduction\n## GLP-1 and liraglutide background\n## Neutrophils and NETs in cancer biology\n## Rationale for PD-1 checkpoint blockade\n# Methods and Results\n## Effects of liraglutide on NET markers in tumor-bearing mice\n## Mechanistic link to neutrophil ROS and NET formation\n## Synergy with PD-1 inhibition and dependence on NETs\n## Long-term CD8+ T-cell responses and rechallenge outcome\n# Conclusions","[{\"question\":\"How does liraglutide affect neutrophil extracellular traps (NETs) in cancer models?\",\"answer\":\"Liraglutide substantially decreases circulating NET markers and reduces NETs in the tumor microenvironment. In vitro, it reduces NET formation by inhibiting neutrophil ROS.\"},{\"question\":\"What is the relationship between liraglutide and PD-1 checkpoint blockade?\",\"answer\":\"Liraglutide enhances the anti-tumoral efficiency of PD-1 inhibition in Lewis lung cancer and Hepa1-6 tumor-bearing mice. This enhancement is dependent on NETs.\"},{\"question\":\"What happens to treatment efficacy when NETs are removed?\",\"answer\":\"Removal of NETs significantly weakens the antitumor efficiency of liraglutide, indicating that NETs reduction is a key contributor to the therapeutic effect.\"}]","Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps | PDF",1790015643,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e7b2193d66960894556a71137dacb78.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d95525e4ac722e4494150b3075814d9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d0b5435061053bad475e9f38797f639.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2976864c6b3525de7c33a13bd4170231.webp",980,1287]